Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.27 USD | +2.62% | +3.81% | -8.20% |
05-16 | AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft | MT |
05-02 | Transcript : AxoGen, Inc., Q1 2024 Earnings Call, May 02, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.20% | 267M | |
+10.03% | 223B | |
+13.59% | 194B | |
+20.01% | 141B | |
+30.83% | 109B | |
+2.05% | 64.85B | |
+15.38% | 52.7B | |
+3.96% | 51.77B | |
+8.37% | 44.12B | |
+3.27% | 36.21B |
- Stock Market
- Equities
- AXGN Stock
- News AxoGen, Inc.
- AxoGen : Canaccord Genuity Adjusts AxoGen PT to $24 From $21, Maintains Hold Rating